10,000+ stock pitches from top investors available on joinyellowbrick.com
BAKER BROS. ADVISORS LP 13F Holdings
Holdings from the most recent 13F from BAKER BROS. ADVISORS LP
Filed: 2021-02-16 (Q4 2020) | Holdings: 126 | Value: $26.5B | Filing Link
PREMIUM
Author Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Filing Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Holding Returns | |||||||
|---|---|---|---|---|---|---|---|
| Stock | Put/Call | Change | Holding Pct | Value | Current Return | 3M Return | 1Y Return |
| SGEN - Seagen Inc. | 31.19% | $8.3B | -6.87% | -21.86% | |||
| BGNE - BeiGene, Ltd. | Reduce 12% $(421.9M) | 11.36% | $3.0B | -35.68% | -15.23% | -46.26% | |
| INCY - Incyte Corporation | 10.49% | $2.8B | -20.72% | +0.26% | -17.34% | ||
| ACAD - ACADIA Pharmaceuticals Inc. | 8.44% | $2.2B | -55.98% | -56.67% | -45.65% | ||
| KOD - Kodiak Sciences Inc. | Add 12% ($224.4M) | 7.68% | $2.0B | -97.50% | -37.91% | -60.31% | |
| ALXN - Alexion Pharmaceuticals, Inc. | 5.16% | $1.4B | +11.15% | ||||
| PRLD - Prelude Therapeutics Incorporated | 2.73% | $724.0M | -98.95% | -50.50% | -88.15% | ||
| BMRN - BioMarin Pharmaceutical Inc. | 2.51% | $665.5M | -31.31% | -8.52% | +6.81% | ||
| NVTA - Invitae Corporation | Add 32% ($158.8M) | 2.46% | $654.3M | -45.38% | -80.60% | ||
| ASND - Ascendis Pharma A/S | 2.22% | $590.4M | +1.45% | -15.51% | -28.52% | ||
| ABCL - AbCellera Biologics Inc. | New Purchase | 1.58% | $420.5M | -95.43% | -22.69% | -78.96% | |
| MRTX - Mirati Therapeutics, Inc. | 1.17% | $309.6M | -22.13% | -54.42% | |||
| ARGX - argenx SE | 1.13% | $299.8M | +58.29% | -23.34% | -20.51% | ||
| IGMS - IGM Biosciences, Inc. | 1.05% | $277.7M | -98.70% | -30.13% | -83.32% | ||
| MDGL - Madrigal Pharmaceuticals, Inc. | 0.63% | $166.7M | +128.75% | +11.36% | -28.66% | ||
| AMRN - Amarin Corporation plc | Reduce 13% $(19.7M) | 0.52% | $136.9M | -92.44% | -43.62% | -56.28% | |
| HRTX - Heron Therapeutics, Inc. | 0.48% | $126.9M | -89.86% | -26.93% | -57.19% | ||
| KYMR - Kymera Therapeutics, Inc. | 0.46% | $121.5M | -50.60% | -25.48% | -36.00% | ||
| ALLK - Allakos Inc. | Add 2% ($2.2M) | 0.38% | $100.0M | -24.81% | -95.53% | ||
| CERS - Cerus Corporation | 0.36% | $94.9M | -83.33% | -24.08% | -29.13% | ||
| BCRX - BioCryst Pharmaceuticals, Inc. | 0.36% | $94.6M | +5.38% | +40.96% | +87.62% | ||
| PACB - Pacific Biosciences of California, Inc. | Reduce 1% $(1.2M) | 0.31% | $83.1M | -97.88% | -48.55% | -75.74% | |
| ZYME - Zymeworks Inc. | 0.30% | $80.7M | -72.12% | -27.49% | -82.78% | ||
| INSM - Insmed Incorporated | Reduce 5% $(3.9M) | 0.27% | $71.8M | +68.39% | -37.12% | -43.20% | |
| FMTX - Forma Therapeutics Holdings, Inc. | Add 14% ($8.8M) | 0.27% | $70.7M | -32.39% | -73.04% | ||
| RYTM - Rhythm Pharmaceuticals, Inc. | Reduce 6% $(4.6M) | 0.26% | $68.8M | +111.34% | -22.83% | -73.47% | |
| NBIX - Neurocrine Biosciences, Inc. | 0.24% | $64.9M | +9.49% | -17.16% | -24.64% | ||
| AXSM - Axsome Therapeutics, Inc. | Reduce 19% $(14.7M) | 0.24% | $63.5M | +42.22% | -20.26% | -58.87% | |
| RARE - Ultragenyx Pharmaceutical Inc. | New Purchase | 0.23% | $61.5M | -76.27% | -23.08% | -53.11% | |
| NRIX - Nurix Therapeutics, Inc. | 0.22% | $58.8M | -73.59% | -35.83% | -61.59% | ||
| BCEL - Atreca, Inc. | 0.21% | $57.1M | -49.89% | -91.35% | |||
| NLTX - Neoleukin Therapeutics, Inc. | 0.20% | $53.9M | |||||
| ADAP - Adaptimmune Therapeutics plc | Add 55% ($18.9M) | 0.20% | $53.0M | -95.86% | -30.27% | -57.57% | |
| APLS - Apellis Pharmaceuticals, Inc. | 0.19% | $51.3M | -62.32% | +18.09% | +0.09% | ||
| KNSA - Kiniksa Pharmaceuticals, Ltd. | 0.19% | $49.5M | +24.65% | -36.22% | -50.16% | ||
| ADCT - ADC Therapeutics SA | Reduce 16% $(8.6M) | 0.17% | $45.4M | -90.03% | -30.90% | -50.45% | |
| ALGS - Aligos Therapeutics, Inc. | New Purchase | 0.17% | $44.5M | -99.34% | -29.71% | -92.56% | |
| HZNP - Horizon Therapeutics Public Ltd Co | Reduce 10% $(4.9M) | 0.17% | $43.8M | +8.34% | +9.00% | ||
| KRYS - Krystal Biotech, Inc. | Reduce 10% $(4.6M) | 0.16% | $41.9M | +75.51% | -6.80% | -8.97% | |
| CCXI - ChemoCentryx, Inc. | Reduce 27% $(15.1M) | 0.15% | $40.7M | -83.55% | -49.43% | ||
| GBT - Global Blood Therapeutics, Inc. | 0.15% | $39.9M | -27.55% | -34.16% | |||
| DBVT - DBV Technologies S.A. | 0.14% | $38.3M | -85.58% | +11.05% | -74.96% | ||
| OPT - Opthea Limited | New Purchase | 0.14% | $37.1M | -26.46% | -46.67% | ||
| MRUS - Merus N.V. | 0.13% | $35.7M | +129.80% | -7.62% | +8.57% | ||
| ALKS - Alkermes plc | Add 13% ($3.5M) | 0.12% | $30.6M | +57.51% | +11.80% | +28.35% | |
| FREQ - Frequency Therapeutics, Inc. | New Purchase | 0.11% | $30.2M | ||||
| PTGX - Protagonist Therapeutics, Inc. | Reduce 10% $(3.2M) | 0.11% | $29.0M | +77.06% | +12.16% | -5.00% | |
| BCAB - BioAtla, Inc. | New Purchase | 0.11% | $28.1M | -99.22% | -13.09% | -87.46% | |
| RETA - Reata Pharmaceuticals, Inc. | New Purchase | 0.10% | $27.7M | -36.28% | -78.87% | ||
| ATHA - Athira Pharma, Inc. | New Purchase | 0.10% | $27.6M | -98.49% | -6.52% | -54.40% | |
| AGLE - Aeglea BioTherapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| ALT - Altimmune, Inc. | Reduce 100% | 0.00% | $0.00 | -61.05% | -35.55% | -65.91% | |
| ASMB - Assembly Biosciences, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| AUPH - Aurinia Pharmaceuticals Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| CBAY - Cymabay Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| EXAS - Exact Sciences Corporation | Reduce 100% | 0.00% | $0.00 | -58.32% | -36.44% | -49.80% | |
| MYOK - MyoKardia, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| N/A - Neurocrine Biosciences, Inc. | Reduce 100% | 0.00% | $0.00 | ||||